Biodexa Pharmaceuticals Plc (BDRX) 10-Year Financial Performance & Capital Metrics

BDRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Show more

Revenue $0 -100.0%
EBITDA -$9M -17.5%
Net Income -$6M +19.1%
EPS (Diluted) -115700.00 -405.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -88.14% +51.2%
ROIC -210.63% +97.9%
Debt/Equity 0.09 -11.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-92.93%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM58.26%

ROCE

10Y Avg-81.35%

5Y Avg-130.98%

3Y Avg-144.32%

Latest-124.99%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.38M	1.32M	989K	1.94M	674K	343K	578K	699K	381K	0
Revenue Growth %	7.76%	-0.04%	-0.25%	0.96%	-0.65%	-0.49%	0.69%	0.21%	-0.45%	-1%
Cost of Goods Sold+	70K	7.73M	8.33M	9.36M	7.84M	6.07M	4.65M	5.11M	4.07M	5.44M
COGS % of Revenue	0.05%	5.84%	8.42%	4.83%	11.64%	17.69%	8.05%	7.31%	10.67%	-
Gross Profit+	1.3M	-6.41M	-7.34M	-7.42M	-7.17M	-5.72M	-4.08M	-4.41M	-3.69M	-5.44M
Gross Margin %	0.95%	-4.84%	-7.42%	-3.83%	-10.64%	-16.69%	-7.05%	-6.31%	-9.67%	-
Gross Profit Growth %	7.31%	-5.91%	-0.15%	-0.01%	0.03%	0.2%	0.29%	-0.08%	0.16%	-0.48%
Operating Expenses+	12.59M	2.07M	5.54M	4.39M	3.67M	17.32M	2.92M	4.52M	4.33M	3.76M
OpEx % of Revenue	9.15%	1.57%	5.6%	2.27%	5.44%	50.48%	5.06%	6.47%	11.36%	-
Selling, General & Admin	2.69M	3.25M	4.44M	4.39M	4.16M	4.96M	2.95M	4.54M	4.34M	3.79M
SG&A % of Revenue	1.95%	2.45%	4.49%	2.27%	6.18%	14.45%	5.1%	6.5%	11.4%	-
Research & Development	8.71M	7.73M	9.83M	9.36M	7.84M	16.15M	4.65M	5.11M	4.07M	5.44M
R&D % of Revenue	6.33%	5.84%	9.94%	4.83%	11.64%	47.07%	8.05%	7.31%	10.67%	-
Other Operating Expenses	0	0	0	0	-8.34M	-3.79M	-4.68M	-5.13M	-4.08M	-5.47M
Operating Income+	-10.09M	-9.65M	-11.78M	-11.81M	-11.32M	-23.04M	-7M	-8.93M	-8.01M	-9.2M
Operating Margin %	-7.34%	-7.3%	-11.91%	-6.1%	-16.79%	-67.17%	-12.11%	-12.78%	-21.03%	-
Operating Income Growth %	-0.31%	0.04%	-0.22%	-0%	0.04%	-1.04%	0.7%	-0.28%	0.1%	-0.15%
EBITDA+	-9.36M	-5.3M	-10.61M	-10.7M	-10.03M	-21.82M	-6.59M	-8.76M	-7.73M	-9.08M
EBITDA Margin %	-6.8%	-4.01%	-10.73%	-5.52%	-14.89%	-63.62%	-11.41%	-12.53%	-20.29%	-
EBITDA Growth %	-0.27%	0.43%	-1%	-0.01%	0.06%	-1.18%	0.7%	-0.33%	0.12%	-0.17%
D&A (Non-Cash Add-back)	736K	4.35M	1.17M	1.11M	1.28M	1.22M	403K	174K	283K	117K
EBIT	-11.23M	-8.31M	-12.86M	-11.81M	-10.83M	-23.44M	-6.06M	-8.44M	-7.44M	-9.2M
Net Interest Income+	48K	91K	-94K	-585K	-89K	-33K	-44K	-24K	42K	2K
Interest Income	48K	91K	15K	2K	8K	1K	0	29K	83K	2K
Interest Expense	0	0	109K	587K	97K	34K	44K	53K	41K	0
Other Income/Expense	1.69M	1.26M	-1.19M	-585K	395K	-430K	892K	444K	529K	3.22M
Pretax Income+	-11.23M	-8.39M	-12.97M	-12.4M	-10.92M	-23.47M	-6.11M	-8.49M	-7.49M	-5.98M
Pretax Margin %	-8.17%	-6.34%	-13.11%	-6.4%	-16.21%	-68.43%	-10.56%	-12.14%	-19.65%	-
Income Tax+	-1.13M	-2.23M	-1.26M	-2.03M	-1.78M	-1.28M	-646K	-832K	-406K	-250K
Effective Tax Rate %	0.9%	0.73%	0.9%	0.84%	0.92%	0.95%	0.89%	0.9%	0.95%	0.96%
Net Income+	-10.1M	-6.16M	-11.71M	-10.37M	-10.09M	-22.19M	-5.46M	-7.66M	-7.08M	-5.73M
Net Margin %	-7.34%	-4.66%	-11.84%	-5.35%	-14.96%	-64.69%	-9.45%	-10.95%	-18.58%	-
Net Income Growth %	-0.14%	0.39%	-0.9%	0.11%	0.03%	-1.2%	0.75%	-0.4%	0.08%	0.19%
Net Income (Continuing)	-10.1M	-6.16M	-11.71M	-10.37M	-9.14M	-22.19M	-5.46M	-7.66M	-7.08M	-5.73M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-352500.00	-494300.00	-22900.00	-115700.00
EPS Growth %	-0.14%	-1%	0.2%	0.06%	0.93%	0.56%	0.75%	-0.4%	0.95%	-4.05%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-352500.00	-494300.00	-22900.00	-115700.00
Diluted Shares Outstanding	0	0	0	0	3	15	15	15	309	619.52K
Basic Shares Outstanding	0	0	0	0	3	15	15	15	309	619.52K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.33M	22.3M	18.58M	5.62M	13.74M	9.28M	11.76M	4.69M	7.03M	8.81M
Cash & Short-Term Investments	16.18M	17.61M	13.2M	2.34M	10.93M	7.55M	10.06M	2.84M	5.97M	1.67M
Cash Only	16.18M	17.61M	13.2M	2.34M	10.93M	7.55M	10.06M	2.84M	5.97M	1.67M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	985K	1.43M	2.23M	89K	1.81M	95K	33K	329K	704K	715K
Days Sales Outstanding	261.47	393.97	823.74	16.76	980.73	101.09	20.84	171.8	674.44	-
Inventory	459K	817K	941K	0	0	0	0	0	-704K	0
Days Inventory Outstanding	2.39K	38.58	41.24	-	-	-	-	-	-	-
Other Current Assets	2.03M	1.86M	1.58M	3.05M	847K	1.38M	1.06M	1.15M	704K	0
Total Non-Current Assets+	43.71M	34.39M	30.64M	14.83M	17.16M	542K	1.15M	837K	3.51M	5.97M
Property, Plant & Equipment	1.98M	2.77M	2.53M	1.98M	2.15M	542K	1.15M	831K	571K	324K
Fixed Asset Turnover	0.69x	0.48x	0.39x	0.98x	0.31x	0.63x	0.50x	0.84x	0.67x	-
Goodwill	12.46M	14.49M	13.44M	2.29M	2.29M	0	0	0	0	0
Intangible Assets	28.88M	16.68M	14.2M	10.08M	10.09M	0	0	6K	2.94M	5.65M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	387K	448K	465K	469K	2.63M	0	0	0	0	0
Total Assets+	64.04M	56.69M	49.22M	20.44M	30.89M	9.82M	12.91M	5.53M	10.54M	14.78M
Asset Turnover	0.02x	0.02x	0.02x	0.09x	0.02x	0.03x	0.04x	0.13x	0.04x	-
Asset Growth %	0.37%	-0.11%	-0.13%	-0.58%	0.51%	-0.68%	0.32%	-0.57%	0.91%	0.4%
Total Current Liabilities+	9.1M	9.35M	8.36M	2.47M	5.67M	2.99M	1.84M	1.9M	5.57M	5.03M
Accounts Payable	2.29M	3.27M	2.27M	286K	725K	337K	485K	339K	314K	707K
Days Payables Outstanding	11.91K	154.31	99.52	11.15	33.74	20.27	38.04	24.21	28.18	47.46
Short-Term Debt	372K	507K	322K	288K	179K	107K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	68K	0	197K	0	1000K
Other Current Liabilities	3.27M	3.54M	2.64M	792K	2.77M	1.62M	664K	386K	4.23M	921K
Current Ratio	2.23x	2.39x	2.22x	2.27x	2.42x	3.10x	6.39x	2.47x	1.26x	1.75x
Quick Ratio	2.18x	2.30x	2.11x	2.27x	2.42x	3.10x	6.39x	2.47x	1.39x	1.75x
Cash Conversion Cycle	-9.26K	278.24	765.46	-	-	-	-	-	-	-
Total Non-Current Liabilities+	8.05M	1.62M	6.18M	1.05M	5.67M	110K	619.53K	463K	295K	1.42M
Long-Term Debt	1.44M	1.57M	6.16M	714K	4.76M	0	0	0	0	0
Capital Lease Obligations	68K	52K	29K	170K	912K	60K	620K	463K	295K	118K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.55M	0	0	165K	0	50K	-469	0	0	1.31M
Total Liabilities	17.15M	10.96M	14.55M	3.52M	11.34M	3.1M	2.46M	2.36M	5.86M	6.46M
Total Debt+	1.95M	2.16M	6.55M	1.25M	6.08M	260K	766K	624K	464K	727K
Net Debt	-14.22M	-15.45M	-6.66M	-1.09M	-4.85M	-7.29M	-9.29M	-2.21M	-5.51M	-942K
Debt / Equity	0.04x	0.05x	0.19x	0.07x	0.31x	0.04x	0.07x	0.20x	0.10x	0.09x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-108.04x	-20.13x	-116.68x	-677.65x	-159.05x	-168.53x	-195.46x	-
Total Equity+	46.89M	45.72M	34.68M	16.92M	19.56M	6.72M	10.45M	3.16M	4.68M	8.32M
Equity Growth %	0.12%	-0.02%	-0.24%	-0.51%	0.16%	-0.66%	0.56%	-0.7%	0.48%	0.78%
Book Value per Share	-	-	-	-	999999.00	447866.67	696831.27	210800.00	15139.16	13.43
Total Shareholders' Equity	46.89M	45.72M	34.68M	16.92M	19.56M	6.72M	10.45M	3.16M	4.68M	8.32M
Common Stock	2K	2K	3K	3K	23K	63K	98.47K	108.34K	1.19M	6.69M
Retained Earnings	-39.15M	-59.11M	-74.65M	-89.72M	-99.84M	-122.43M	-127.8M	-135.34M	-144.77M	-150.42M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	54.39M	57.62M	56.39M	53.7M	53.49M	54.72M	53M	53M	61.52M	53M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.42M	-13.09M	-12.95M	-13.45M	-6.49M	-9.3M	-6.01M	-7.05M	-6.83M	-12.26M
Operating CF Margin %	-9.03%	-9.89%	-13.1%	-6.94%	-9.63%	-27.12%	-10.39%	-10.08%	-17.92%	-
Operating CF Growth %	-1.28%	-0.05%	0.01%	-0.04%	0.52%	-0.43%	0.35%	-0.17%	0.03%	-0.8%
Net Income	-10.1M	-20.16M	-16.06M	-15.03M	-10.09M	-22.19M	-5.46M	-7.66M	-7.08M	-5.73M
Depreciation & Amortization	736K	4.35M	1.17M	1.11M	1.28M	1.22M	403K	343K	283K	254K
Stock-Based Compensation	170K	0	0	0	-34K	-404K	89K	123K	28K	283K
Deferred Taxes	1.43M	0	0	0	-1.78M	13.2M	469K	-832K	-406K	-250K
Other Non-Cash Items	-1.63M	3.21M	3.11M	-1.07M	2.33M	430K	-892K	454K	397K	-3.08M
Working Capital Changes	-1.6M	-479K	-1.17M	1.54M	1.8M	-1.56M	-617K	520K	-49K	-3.74M
Change in Receivables	-1.54M	-242K	-968K	1.03M	725K	493K	-487K	7K	365K	-5.97M
Change in Inventory	-62K	-237K	-202K	347K	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-1.53M	-1.2M	-1.47M	9.04M	-3.81M	2.57M	-278K	-220K	-265K	-598K
Capital Expenditures	-922K	-1.35M	-707K	-244K	-319K	-209K	-320K	-62K	-26K	-9K
CapEx % of Revenue	0.67%	1.02%	0.71%	0.13%	0.47%	0.61%	0.55%	0.09%	0.07%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	50K	145K	-763K	9.29M	8K	144K	42K	-158K	-239K	-589K
Cash from Financing+	-219K	15.26M	10.28M	-6.47M	18.73M	3.08M	8.8M	47K	10.23M	8.56M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-5K	15.49M	-136K	-587K	766K	-476K	-15K	-18K	-13K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.34M	-14.43M	-13.66M	-13.69M	-6.81M	-9.51M	-6.33M	-7.11M	-7.09M	-13.04M
FCF Margin %	-9.7%	-10.91%	-13.81%	-7.07%	-10.1%	-27.73%	-10.95%	-10.17%	-18.61%	-
FCF Growth %	-1.06%	-0.08%	0.05%	-0%	0.5%	-0.4%	0.33%	-0.12%	0%	-0.84%
FCF per Share	-	-	-	-	-999999.00	-634000.00	-421866.67	-474000.00	-22941.75	-21.04
FCF Conversion (FCF/Net Income)	1.23x	2.12x	1.11x	1.30x	0.64x	0.42x	1.10x	0.92x	0.96x	2.14x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.73%	-13.31%	-29.12%	-40.19%	-55.29%	-168.89%	-63.6%	-112.47%	-180.59%	-88.14%
Return on Invested Capital (ROIC)	-32.72%	-23%	-30.3%	-40.42%	-55.58%	-244.34%	-1768.75%	-634.53%	-9934.71%	-210.63%
Gross Margin	94.91%	-484.28%	-742.16%	-382.92%	-1063.65%	-1669.1%	-705.19%	-631.19%	-967.45%	-
Net Margin	-734.47%	-465.68%	-1183.52%	-534.98%	-1496.29%	-6469.1%	-944.64%	-1095.28%	-1858.01%	-
Debt / Equity	0.04x	0.05x	0.19x	0.07x	0.31x	0.04x	0.07x	0.20x	0.10x	0.09x
Interest Coverage	-	-	-108.04x	-20.13x	-116.68x	-677.65x	-159.05x	-168.53x	-195.46x	-
FCF Conversion	1.23x	2.12x	1.11x	1.30x	0.64x	0.42x	1.10x	0.92x	0.96x	2.14x
Revenue Growth	775.8%	-3.78%	-25.25%	95.96%	-65.22%	-49.11%	68.51%	20.93%	-45.49%	-100%

Frequently Asked Questions

Growth & Financials

Biodexa Pharmaceuticals Plc (BDRX) reported $0.1M in revenue for fiscal year 2024.

Biodexa Pharmaceuticals Plc (BDRX) saw revenue decline by 100.0% over the past year.

Biodexa Pharmaceuticals Plc (BDRX) reported a net loss of $13.0M for fiscal year 2024.

Dividend & Returns

Biodexa Pharmaceuticals Plc (BDRX) has a return on equity (ROE) of -88.1%. Negative ROE indicates the company is unprofitable.

Biodexa Pharmaceuticals Plc (BDRX) had negative free cash flow of $19.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Biodexa Pharmaceuticals Plc (BDRX) 10-Year Financial Performance & Capital Metrics

BDRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0 -100.0%
EBITDA -$9M -17.5%
Net Income -$6M +19.1%
EPS (Diluted) -115700.00 -405.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -88.14% +51.2%
ROIC -210.63% +97.9%
Debt/Equity 0.09 -11.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-92.93%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM58.26%

ROCE

10Y Avg-81.35%

5Y Avg-130.98%

3Y Avg-144.32%

Latest-124.99%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.38M	1.32M	989K	1.94M	674K	343K	578K	699K	381K	0
Revenue Growth %	7.76%	-0.04%	-0.25%	0.96%	-0.65%	-0.49%	0.69%	0.21%	-0.45%	-1%
Cost of Goods Sold+	70K	7.73M	8.33M	9.36M	7.84M	6.07M	4.65M	5.11M	4.07M	5.44M
COGS % of Revenue	0.05%	5.84%	8.42%	4.83%	11.64%	17.69%	8.05%	7.31%	10.67%	-
Gross Profit+	1.3M	-6.41M	-7.34M	-7.42M	-7.17M	-5.72M	-4.08M	-4.41M	-3.69M	-5.44M
Gross Margin %	0.95%	-4.84%	-7.42%	-3.83%	-10.64%	-16.69%	-7.05%	-6.31%	-9.67%	-
Gross Profit Growth %	7.31%	-5.91%	-0.15%	-0.01%	0.03%	0.2%	0.29%	-0.08%	0.16%	-0.48%
Operating Expenses+	12.59M	2.07M	5.54M	4.39M	3.67M	17.32M	2.92M	4.52M	4.33M	3.76M
OpEx % of Revenue	9.15%	1.57%	5.6%	2.27%	5.44%	50.48%	5.06%	6.47%	11.36%	-
Selling, General & Admin	2.69M	3.25M	4.44M	4.39M	4.16M	4.96M	2.95M	4.54M	4.34M	3.79M
SG&A % of Revenue	1.95%	2.45%	4.49%	2.27%	6.18%	14.45%	5.1%	6.5%	11.4%	-
Research & Development	8.71M	7.73M	9.83M	9.36M	7.84M	16.15M	4.65M	5.11M	4.07M	5.44M
R&D % of Revenue	6.33%	5.84%	9.94%	4.83%	11.64%	47.07%	8.05%	7.31%	10.67%	-
Other Operating Expenses	0	0	0	0	-8.34M	-3.79M	-4.68M	-5.13M	-4.08M	-5.47M
Operating Income+	-10.09M	-9.65M	-11.78M	-11.81M	-11.32M	-23.04M	-7M	-8.93M	-8.01M	-9.2M
Operating Margin %	-7.34%	-7.3%	-11.91%	-6.1%	-16.79%	-67.17%	-12.11%	-12.78%	-21.03%	-
Operating Income Growth %	-0.31%	0.04%	-0.22%	-0%	0.04%	-1.04%	0.7%	-0.28%	0.1%	-0.15%
EBITDA+	-9.36M	-5.3M	-10.61M	-10.7M	-10.03M	-21.82M	-6.59M	-8.76M	-7.73M	-9.08M
EBITDA Margin %	-6.8%	-4.01%	-10.73%	-5.52%	-14.89%	-63.62%	-11.41%	-12.53%	-20.29%	-
EBITDA Growth %	-0.27%	0.43%	-1%	-0.01%	0.06%	-1.18%	0.7%	-0.33%	0.12%	-0.17%
D&A (Non-Cash Add-back)	736K	4.35M	1.17M	1.11M	1.28M	1.22M	403K	174K	283K	117K
EBIT	-11.23M	-8.31M	-12.86M	-11.81M	-10.83M	-23.44M	-6.06M	-8.44M	-7.44M	-9.2M
Net Interest Income+	48K	91K	-94K	-585K	-89K	-33K	-44K	-24K	42K	2K
Interest Income	48K	91K	15K	2K	8K	1K	0	29K	83K	2K
Interest Expense	0	0	109K	587K	97K	34K	44K	53K	41K	0
Other Income/Expense	1.69M	1.26M	-1.19M	-585K	395K	-430K	892K	444K	529K	3.22M
Pretax Income+	-11.23M	-8.39M	-12.97M	-12.4M	-10.92M	-23.47M	-6.11M	-8.49M	-7.49M	-5.98M
Pretax Margin %	-8.17%	-6.34%	-13.11%	-6.4%	-16.21%	-68.43%	-10.56%	-12.14%	-19.65%	-
Income Tax+	-1.13M	-2.23M	-1.26M	-2.03M	-1.78M	-1.28M	-646K	-832K	-406K	-250K
Effective Tax Rate %	0.9%	0.73%	0.9%	0.84%	0.92%	0.95%	0.89%	0.9%	0.95%	0.96%
Net Income+	-10.1M	-6.16M	-11.71M	-10.37M	-10.09M	-22.19M	-5.46M	-7.66M	-7.08M	-5.73M
Net Margin %	-7.34%	-4.66%	-11.84%	-5.35%	-14.96%	-64.69%	-9.45%	-10.95%	-18.58%	-
Net Income Growth %	-0.14%	0.39%	-0.9%	0.11%	0.03%	-1.2%	0.75%	-0.4%	0.08%	0.19%
Net Income (Continuing)	-10.1M	-6.16M	-11.71M	-10.37M	-9.14M	-22.19M	-5.46M	-7.66M	-7.08M	-5.73M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-352500.00	-494300.00	-22900.00	-115700.00
EPS Growth %	-0.14%	-1%	0.2%	0.06%	0.93%	0.56%	0.75%	-0.4%	0.95%	-4.05%
EPS (Basic)	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-999999.00	-352500.00	-494300.00	-22900.00	-115700.00
Diluted Shares Outstanding	0	0	0	0	3	15	15	15	309	619.52K
Basic Shares Outstanding	0	0	0	0	3	15	15	15	309	619.52K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.33M	22.3M	18.58M	5.62M	13.74M	9.28M	11.76M	4.69M	7.03M	8.81M
Cash & Short-Term Investments	16.18M	17.61M	13.2M	2.34M	10.93M	7.55M	10.06M	2.84M	5.97M	1.67M
Cash Only	16.18M	17.61M	13.2M	2.34M	10.93M	7.55M	10.06M	2.84M	5.97M	1.67M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	985K	1.43M	2.23M	89K	1.81M	95K	33K	329K	704K	715K
Days Sales Outstanding	261.47	393.97	823.74	16.76	980.73	101.09	20.84	171.8	674.44	-
Inventory	459K	817K	941K	0	0	0	0	0	-704K	0
Days Inventory Outstanding	2.39K	38.58	41.24	-	-	-	-	-	-	-
Other Current Assets	2.03M	1.86M	1.58M	3.05M	847K	1.38M	1.06M	1.15M	704K	0
Total Non-Current Assets+	43.71M	34.39M	30.64M	14.83M	17.16M	542K	1.15M	837K	3.51M	5.97M
Property, Plant & Equipment	1.98M	2.77M	2.53M	1.98M	2.15M	542K	1.15M	831K	571K	324K
Fixed Asset Turnover	0.69x	0.48x	0.39x	0.98x	0.31x	0.63x	0.50x	0.84x	0.67x	-
Goodwill	12.46M	14.49M	13.44M	2.29M	2.29M	0	0	0	0	0
Intangible Assets	28.88M	16.68M	14.2M	10.08M	10.09M	0	0	6K	2.94M	5.65M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	387K	448K	465K	469K	2.63M	0	0	0	0	0
Total Assets+	64.04M	56.69M	49.22M	20.44M	30.89M	9.82M	12.91M	5.53M	10.54M	14.78M
Asset Turnover	0.02x	0.02x	0.02x	0.09x	0.02x	0.03x	0.04x	0.13x	0.04x	-
Asset Growth %	0.37%	-0.11%	-0.13%	-0.58%	0.51%	-0.68%	0.32%	-0.57%	0.91%	0.4%
Total Current Liabilities+	9.1M	9.35M	8.36M	2.47M	5.67M	2.99M	1.84M	1.9M	5.57M	5.03M
Accounts Payable	2.29M	3.27M	2.27M	286K	725K	337K	485K	339K	314K	707K
Days Payables Outstanding	11.91K	154.31	99.52	11.15	33.74	20.27	38.04	24.21	28.18	47.46
Short-Term Debt	372K	507K	322K	288K	179K	107K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	68K	0	197K	0	1000K
Other Current Liabilities	3.27M	3.54M	2.64M	792K	2.77M	1.62M	664K	386K	4.23M	921K
Current Ratio	2.23x	2.39x	2.22x	2.27x	2.42x	3.10x	6.39x	2.47x	1.26x	1.75x
Quick Ratio	2.18x	2.30x	2.11x	2.27x	2.42x	3.10x	6.39x	2.47x	1.39x	1.75x
Cash Conversion Cycle	-9.26K	278.24	765.46	-	-	-	-	-	-	-
Total Non-Current Liabilities+	8.05M	1.62M	6.18M	1.05M	5.67M	110K	619.53K	463K	295K	1.42M
Long-Term Debt	1.44M	1.57M	6.16M	714K	4.76M	0	0	0	0	0
Capital Lease Obligations	68K	52K	29K	170K	912K	60K	620K	463K	295K	118K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.55M	0	0	165K	0	50K	-469	0	0	1.31M
Total Liabilities	17.15M	10.96M	14.55M	3.52M	11.34M	3.1M	2.46M	2.36M	5.86M	6.46M
Total Debt+	1.95M	2.16M	6.55M	1.25M	6.08M	260K	766K	624K	464K	727K
Net Debt	-14.22M	-15.45M	-6.66M	-1.09M	-4.85M	-7.29M	-9.29M	-2.21M	-5.51M	-942K
Debt / Equity	0.04x	0.05x	0.19x	0.07x	0.31x	0.04x	0.07x	0.20x	0.10x	0.09x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-108.04x	-20.13x	-116.68x	-677.65x	-159.05x	-168.53x	-195.46x	-
Total Equity+	46.89M	45.72M	34.68M	16.92M	19.56M	6.72M	10.45M	3.16M	4.68M	8.32M
Equity Growth %	0.12%	-0.02%	-0.24%	-0.51%	0.16%	-0.66%	0.56%	-0.7%	0.48%	0.78%
Book Value per Share	-	-	-	-	999999.00	447866.67	696831.27	210800.00	15139.16	13.43
Total Shareholders' Equity	46.89M	45.72M	34.68M	16.92M	19.56M	6.72M	10.45M	3.16M	4.68M	8.32M
Common Stock	2K	2K	3K	3K	23K	63K	98.47K	108.34K	1.19M	6.69M
Retained Earnings	-39.15M	-59.11M	-74.65M	-89.72M	-99.84M	-122.43M	-127.8M	-135.34M	-144.77M	-150.42M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	54.39M	57.62M	56.39M	53.7M	53.49M	54.72M	53M	53M	61.52M	53M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.42M	-13.09M	-12.95M	-13.45M	-6.49M	-9.3M	-6.01M	-7.05M	-6.83M	-12.26M
Operating CF Margin %	-9.03%	-9.89%	-13.1%	-6.94%	-9.63%	-27.12%	-10.39%	-10.08%	-17.92%	-
Operating CF Growth %	-1.28%	-0.05%	0.01%	-0.04%	0.52%	-0.43%	0.35%	-0.17%	0.03%	-0.8%
Net Income	-10.1M	-20.16M	-16.06M	-15.03M	-10.09M	-22.19M	-5.46M	-7.66M	-7.08M	-5.73M
Depreciation & Amortization	736K	4.35M	1.17M	1.11M	1.28M	1.22M	403K	343K	283K	254K
Stock-Based Compensation	170K	0	0	0	-34K	-404K	89K	123K	28K	283K
Deferred Taxes	1.43M	0	0	0	-1.78M	13.2M	469K	-832K	-406K	-250K
Other Non-Cash Items	-1.63M	3.21M	3.11M	-1.07M	2.33M	430K	-892K	454K	397K	-3.08M
Working Capital Changes	-1.6M	-479K	-1.17M	1.54M	1.8M	-1.56M	-617K	520K	-49K	-3.74M
Change in Receivables	-1.54M	-242K	-968K	1.03M	725K	493K	-487K	7K	365K	-5.97M
Change in Inventory	-62K	-237K	-202K	347K	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-1.53M	-1.2M	-1.47M	9.04M	-3.81M	2.57M	-278K	-220K	-265K	-598K
Capital Expenditures	-922K	-1.35M	-707K	-244K	-319K	-209K	-320K	-62K	-26K	-9K
CapEx % of Revenue	0.67%	1.02%	0.71%	0.13%	0.47%	0.61%	0.55%	0.09%	0.07%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	50K	145K	-763K	9.29M	8K	144K	42K	-158K	-239K	-589K
Cash from Financing+	-219K	15.26M	10.28M	-6.47M	18.73M	3.08M	8.8M	47K	10.23M	8.56M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-5K	15.49M	-136K	-587K	766K	-476K	-15K	-18K	-13K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.34M	-14.43M	-13.66M	-13.69M	-6.81M	-9.51M	-6.33M	-7.11M	-7.09M	-13.04M
FCF Margin %	-9.7%	-10.91%	-13.81%	-7.07%	-10.1%	-27.73%	-10.95%	-10.17%	-18.61%	-
FCF Growth %	-1.06%	-0.08%	0.05%	-0%	0.5%	-0.4%	0.33%	-0.12%	0%	-0.84%
FCF per Share	-	-	-	-	-999999.00	-634000.00	-421866.67	-474000.00	-22941.75	-21.04
FCF Conversion (FCF/Net Income)	1.23x	2.12x	1.11x	1.30x	0.64x	0.42x	1.10x	0.92x	0.96x	2.14x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.73%	-13.31%	-29.12%	-40.19%	-55.29%	-168.89%	-63.6%	-112.47%	-180.59%	-88.14%
Return on Invested Capital (ROIC)	-32.72%	-23%	-30.3%	-40.42%	-55.58%	-244.34%	-1768.75%	-634.53%	-9934.71%	-210.63%
Gross Margin	94.91%	-484.28%	-742.16%	-382.92%	-1063.65%	-1669.1%	-705.19%	-631.19%	-967.45%	-
Net Margin	-734.47%	-465.68%	-1183.52%	-534.98%	-1496.29%	-6469.1%	-944.64%	-1095.28%	-1858.01%	-
Debt / Equity	0.04x	0.05x	0.19x	0.07x	0.31x	0.04x	0.07x	0.20x	0.10x	0.09x
Interest Coverage	-	-	-108.04x	-20.13x	-116.68x	-677.65x	-159.05x	-168.53x	-195.46x	-
FCF Conversion	1.23x	2.12x	1.11x	1.30x	0.64x	0.42x	1.10x	0.92x	0.96x	2.14x
Revenue Growth	775.8%	-3.78%	-25.25%	95.96%	-65.22%	-49.11%	68.51%	20.93%	-45.49%	-100%

Frequently Asked Questions

Growth & Financials

Biodexa Pharmaceuticals Plc (BDRX) reported $0.1M in revenue for fiscal year 2024.

Biodexa Pharmaceuticals Plc (BDRX) saw revenue decline by 100.0% over the past year.

Biodexa Pharmaceuticals Plc (BDRX) reported a net loss of $13.0M for fiscal year 2024.

Dividend & Returns

Biodexa Pharmaceuticals Plc (BDRX) has a return on equity (ROE) of -88.1%. Negative ROE indicates the company is unprofitable.

Biodexa Pharmaceuticals Plc (BDRX) had negative free cash flow of $19.3M in fiscal year 2024, likely due to heavy capital investments.